Production of bFGF monoclonal antibody and its inhibition of metastasis in Lewis lung carcinoma
- Authors:
- Published online on: July 27, 2017 https://doi.org/10.3892/mmr.2017.7099
- Pages: 4015-4021
-
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor 1 (FGFR1) are associated with drug resistance in lung cancer. In the present study, mouse monoclonal antibodies (mAb) against human bFGF, targeting the binding site of bFGF with FGFR1 were produced, and the antitumor activity and inhibition of metastasis was studied in Lewis lung carcinoma (LLC). A total of four hybridoma cell strains that stably secreted bFGF mAb were obtained. mAbE12 was selected as the most effective for use in the following studies, with a relative affinity constant of 5.66x108 l/mol. mAbE12 was demonstrated to inhibit cell proliferation and tumor growth in vitro and in vivo. Furthermore, mAbE12 blocked migration and metastasis of LLC cells in vitro and in vivo. This occurred due to a mAbE12‑induced upregulation of E‑cadherin expression through the protein kinase B‑glycogen synthase kinase 3 β‑Snail pathway. These results suggested that mAbE12 may be a potential antibody for the treatment of lung cancer.
